Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00003657 · ClinicalTrials.gov registry record · Phase 2
High-dose ICE With Amifostine
A Phase 2 study, sponsored by Dana-Farber Cancer Institute.
- Completed
- Registry status
- Phase 2
- Development phase
- 24
- Enrollment target
NCT00003657: Completed Phase 2 study, sponsored by Dana-Farber Cancer Institute.
NCT00003657 is a Phase 2 study that has completed, run by Dana-Farber Cancer Institute. The registered enrollment target is 24 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (82% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00003657, a Phase 2 study, has completed, sponsored by Dana-Farber Cancer Institute.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 24 participants
- Enrollment target
Study Summary
The purpose of the study is to evaluate the combination of amifostine and high dose chemotherapy with blood stem cell support. Amifostine is a druf developed to protect normal tissues against the toxicities of chemotherapy and radiotherapy and has reduced the side effects of chemotherapy given at conventional doses.
Interventions
- DRUG Carboplatin
- DRUG Etoposide
- DRUG Ifosfamide
- BIOLOGICAL filgrastim
- DRUG Amifostine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 1998-07 |
| Est. Completion | 2002-06 |
| Phase | Phase 2 |
What the finished NCT00003657 record still lists
NCT00003657 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 24 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (82% lower).
The record links to 0 conditions, and to 5 interventions - of which Carboplatin is the first listed.
NCT00003657 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00003657 about?
NCT00003657 is a clinical study titled "High-dose ICE With Amifostine". The purpose of the study is to evaluate the combination of amifostine and high dose chemotherapy with blood stem cell support. Amifostine is a druf developed to protect normal tissues against the toxicities of chemotherapy and radiotherapy and has reduced the side effects of chemotherapy given at co...
What is the current status of trial NCT00003657?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 24 participants. The study started on 1998-07. Estimated completion is 2002-06.
What interventions are being tested in trial NCT00003657?
The interventions under investigation include: Carboplatin (DRUG), Etoposide (DRUG), Ifosfamide (DRUG), filgrastim (BIOLOGICAL), Amifostine (DRUG).
Who is sponsoring clinical trial NCT00003657?
This trial is sponsored by Dana-Farber Cancer Institute, which has 781 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00003657's enrollment target sits among peer trials
24 1756th of 2000 higher than 217 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02331979 · 24 participants · NA
Improving Bladder Function in SCI by Neuromodulation
- NCT03096197 · 24 participants · NA
Exoskeleton and Spinal Cord Stimulation for SCI
- NCT03223922 · 24 participants · NA
Neurocognitive Functioning With Genu-Sparing Whole Brain Radiation Therapy for Brain Metastases
- NCT03326921 · 24 participants · Phase 1
HA-1 T TCR T Cell Immunotherapy for the Treatment of Patients With Relapsed or Refractory Acute Leukemia After Donor Stem Cell Transplant
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia